CRACR2B Antibody

What is CRACR2B and what biological functions does it perform?

CRACR2B (Calcium Release Activated Channel Regulator 2B) is a protein coding gene that plays an essential role in store-operated Ca2+ entry (SOCE). Gene Ontology (GO) annotations for this protein include calcium ion binding functionality . The protein is primarily involved in biological processes including cellular protein localization, regulation of store-operated calcium entry, and store-operated calcium entry . CRACR2B is predominantly localized in the cytoplasm and functions as part of the calcium signaling pathway in cells .

How does CRACR2B differ from its paralog CRACR2A?

CRACR2A and CRACR2B are paralogs with some functional redundancy but distinct expression patterns and biological significance. CRACR2A acts as a cytosolic Ca2+ sensor that modulates multiple steps of CRAC channel activation including the translocation and clustering of Orai1 and STIM1 through direct protein interaction . While both proteins participate in store-operated calcium entry pathways, CRACR2A transcripts are more abundant in immune cells (spleen, thymus, T cells), whereas CRACR2B transcripts are more prevalent in other cell types such as HEK293 cells . Functionally, depletion studies have shown that CRACR2A knockdown has stronger effects on SOCE in T cells, while CRACR2B knockdown more significantly impacts SOCE in HEK293 cells .

What is the protein interaction network of CRACR2B?

According to STRING database analysis, CRACR2B interacts with several proteins in its functional network. Key interaction partners include DYNC1LI1 (cytoplasmic dynein 1 light intermediate chain 1), CARD19 (caspase recruitment domain-containing protein 19), RAB15 (Ras-related protein Rab-15), OR5H2 (olfactory receptor 5H2), and RAB3A (Ras-related protein Rab-3A) . These interactions suggest potential roles for CRACR2B in microtubule-dependent transport, vesicle trafficking, and signaling pathways beyond its established function in calcium homeostasis.

What types of CRACR2B antibodies are available for research applications?

Several types of CRACR2B antibodies are available for research purposes, including:

• Polyclonal antibodies:

  • Rabbit polyclonal antibodies raised against synthetic peptides of human CRACR2B/EFCAB4A

  • These antibodies typically recognize multiple epitopes of the CRACR2B protein

• Monoclonal antibodies:

  • Mouse anti-CRACR2B recombinant antibody (clone 2F10)

  • These offer high specificity for particular epitopes

Each antibody type has specific applications and validation parameters that should be considered when designing experiments.

How should researchers validate CRACR2B antibodies for specific applications?

Proper antibody validation is crucial for experimental success and reproducibility. For CRACR2B antibodies, validation should include:

• Western blot analysis to confirm specificity at the expected molecular weight

• Testing in multiple cell lines with known CRACR2B expression levels (e.g., comparing HEK293 and Jurkat T cells which have different expression patterns)

• RNA interference experiments as negative controls (e.g., testing antibody specificity in CRACR2B-knockdown cells)

• Cross-validation using different antibodies targeting different epitopes

• Testing in the specific application of interest (IHC, ICC-IF, WB, etc.) as antibodies validated for one application may not work in others

Researchers should also review the validation data provided by manufacturers and independent validation initiatives before selecting an antibody.

What are the optimal conditions for using CRACR2B antibodies in Western blot applications?

For Western blot applications using anti-CRACR2B antibodies, researchers should consider the following protocol guidelines:

• Sample preparation:

  • Use appropriate lysis buffers that preserve protein integrity

  • Include protease inhibitors to prevent degradation

  • Denature samples at appropriate temperatures (typically 95°C for 5 minutes)

• Antibody conditions:

  • Use recommended dilutions (e.g., 1-2 μg/ml for rabbit polyclonal antibodies)

  • Optimize incubation time and temperature (typically overnight at 4°C)

  • Use appropriate blocking agents to minimize background

• Detection methods:

  • Select appropriate secondary antibodies based on the host species of the primary antibody

  • Consider enhanced chemiluminescence (ECL) or fluorescence-based detection systems

  • Include positive controls (tissues/cells with known CRACR2B expression) and negative controls

These parameters may require optimization for specific experimental contexts and antibody sources.

How can researchers effectively use CRACR2B antibodies in immunocytochemistry applications?

For immunocytochemistry and immunofluorescence applications using CRACR2B antibodies, researchers should follow these methodological guidelines:

• Cell preparation:

  • Fix cells with paraformaldehyde (typically 4%) or other appropriate fixatives

  • Permeabilize with detergents suitable for cytoplasmic proteins (e.g., 0.1% Triton X-100)

  • Block with appropriate serum or BSA solution to reduce non-specific binding

• Antibody application:

  • Dilute primary antibodies according to manufacturer recommendations

  • Incubate overnight at 4°C or for 1-2 hours at room temperature

  • Use fluorophore-conjugated secondary antibodies appropriate for the microscopy system

• Controls and co-staining:

  • Include negative controls (secondary antibody only, isotype controls)

  • Consider co-staining with markers of cellular compartments to confirm cytoplasmic localization

  • Use DAPI or similar nuclear stains for orientation

Given CRACR2B's cytoplasmic localization , researchers should expect primarily cytoplasmic staining patterns.

How do expression patterns of CRACR2B differ across tissue and cell types, and how does this impact antibody selection?

CRACR2B exhibits distinct expression patterns across different tissues and cell types, which has important implications for antibody selection and experimental design:

Based on these expression patterns , researchers should:

• Select positive control tissues/cells with known high CRACR2B expression (e.g., HEK293)

• Consider tissue-specific antibody validation

• Be aware that detection sensitivity requirements may vary across tissue types

• Account for potential cross-reactivity with the paralog CRACR2A, especially in immune cells

How can researchers design knockdown/knockout experiments to study CRACR2B function while accounting for potential CRACR2A compensation?

When designing functional studies of CRACR2B through genetic manipulation, researchers must consider the potential functional redundancy between CRACR2B and CRACR2A. Evidence suggests that expression of CRACR2A can partially restore SOCE in cells depleted of CRACR2B, indicating functional compensation . Recommended experimental approaches include:

• Single knockdown/knockout designs:

  • Use siRNA targeting CRACR2B specifically

  • Monitor both CRACR2A and CRACR2B expression after knockdown

  • Assess functional outcomes with store-operated calcium entry assays

• Double knockdown/knockout approaches:

  • Simultaneously target both CRACR2A and CRACR2B

  • Compare phenotypes with single knockdowns to identify unique and redundant functions

  • Use rescue experiments with individual proteins to confirm specificity

• Cell type considerations:

  • Select experimental cell types based on research question (e.g., HEK293 for CRACR2B-dominant effects, T cells for CRACR2A-dominant effects)

  • Consider creating stable knockdown cell lines for long-term studies

• Functional readouts:

  • Measure multiple calcium signaling parameters beyond SOCE

  • Consider downstream effects on cellular function (e.g., gene expression, cell activation)

What are the recommended protocols for studying CRACR2B's role in store-operated calcium entry?

To investigate CRACR2B's role in store-operated calcium entry, researchers should implement the following methodological approaches:

• Calcium imaging techniques:

  • Use ratiometric calcium indicators (e.g., Fura-2) to measure intracellular calcium changes

  • Implement store depletion protocols using thapsigargin or ionomycin

  • Measure both peak calcium entry and sustained calcium plateaus

  • Consider using genetically encoded calcium indicators for long-term studies

• Experimental manipulations:

  • Utilize CRACR2B knockdown/overexpression approaches

  • Compare results in cell types with different CRACR2A/CRACR2B expression ratios

  • Use pharmacological inhibitors of SOCE (e.g., 2-APB, CM4620) as controls

• Protein interaction studies:

  • Perform co-immunoprecipitation with Orai1 and STIM1 under store depletion conditions

  • Assess the formation of puncta using fluorescently tagged proteins

  • Use proximity ligation assays to confirm direct interactions

• Calcium-dependent dissociation:

  • Investigate how increasing calcium concentrations affect CRACR2B interactions with SOCE components

  • Compare with CRACR2A behavior, which is known to dissociate from Orai1 and STIM1 at higher calcium concentrations

What are common pitfalls when using CRACR2B antibodies and how can they be addressed?

Researchers frequently encounter challenges when working with CRACR2B antibodies. Here are common issues and solutions:

• Non-specific binding:

  • Problem: Multiple bands in Western blot or diffuse staining in immunocytochemistry

  • Solutions:

    • Increase blocking time/concentration

    • Optimize antibody dilutions

    • Use knockout/knockdown controls to identify specific signals

    • Consider switching to a more specific antibody clone

• Weak or no signal:

  • Problem: Inability to detect CRACR2B despite expected expression

  • Solutions:

    • Confirm CRACR2B expression levels in the cell/tissue type using RT-PCR

    • Optimize protein extraction protocols for cytoplasmic proteins

    • Try epitope retrieval methods for fixed tissues

    • Consider concentration of samples for low-abundance detection

• Antibody degradation:

  • Problem: Decreasing antibody performance over time

  • Solutions:

    • Store antibodies according to manufacturer recommendations

    • Avoid repeated freeze-thaw cycles

    • Use appropriate preservatives

    • Aliquot antibodies for single use

• Cross-reactivity with CRACR2A:

  • Problem: Inability to distinguish between CRACR2A and CRACR2B signals

  • Solutions:

    • Select antibodies validated for specificity between paralogs

    • Use cells with differential expression of CRACR2A/CRACR2B as controls

    • Perform parallel knockdown experiments to confirm specificity

How can researchers distinguish between effects of CRACR2B and its paralog CRACR2A in functional studies?

Distinguishing between CRACR2B and CRACR2A effects is critical for accurate interpretation of research findings. Recommended approaches include:

• Expression profiling:

  • Quantify relative mRNA levels of both proteins in the experimental system using qRT-PCR

  • Assess protein expression levels using validated specific antibodies

  • Create an expression ratio profile as baseline for interpretation

• Selective genetic manipulation:

  • Design highly specific siRNAs targeting unique regions of each transcript

  • Use CRISPR-Cas9 gene editing for complete knockout studies

  • Perform individual and combined knockdowns to assess distinct and overlapping functions

• Functional domain analysis:

  • Focus on structural or functional differences between the proteins

  • Use domain-specific antibodies or tagged constructs

  • Create chimeric proteins to identify functionally distinct regions

• Cell type selection strategy:

  • Leverage natural expression patterns (e.g., use HEK293 cells for CRACR2B-dominant studies and T cells for CRACR2A-dominant studies)

  • Create model systems with controlled expression of each protein

What novel techniques are being developed to study CRACR2B interactions in the SOCE pathway?

Cutting-edge approaches for investigating CRACR2B's role in the SOCE pathway include:

• Advanced imaging technologies:

  • Super-resolution microscopy to visualize CRACR2B-Orai1-STIM1 complexes at nanoscale resolution

  • Live-cell FRET or BRET assays to monitor dynamic protein interactions

  • Lattice light-sheet microscopy for 3D visualization of calcium microdomains

• Proteomics approaches:

  • Proximity labeling methods (BioID, APEX) to identify the complete interactome

  • Hydrogen-deuterium exchange mass spectrometry to map interaction interfaces

  • Cross-linking mass spectrometry to capture transient interactions

• Structural biology:

  • Cryo-EM analysis of CRACR2B alone and in complex with interaction partners

  • X-ray crystallography of key domains to understand calcium binding properties

  • NMR studies of conformational changes upon calcium binding

• Systems biology approaches:

  • Mathematical modeling of calcium dynamics incorporating CRACR2B effects

  • Network analysis comparing CRACR2A and CRACR2B regulatory networks

  • Multi-omics integration to understand downstream effects of CRACR2B modulation

These emerging methodologies promise to provide deeper insights into the molecular mechanisms of CRACR2B function in calcium signaling pathways.

How might understanding CRACR2B function contribute to therapeutic approaches for calcium signaling disorders?

Research on CRACR2B has potential translational implications for disorders involving dysregulated calcium signaling:

• Immune disorders:

  • The differential expression of CRACR2B and CRACR2A in immune versus non-immune cells suggests potential for targeting specific cell populations

  • Modulating CRACR2B might allow for selective regulation of calcium signaling in non-immune cells while preserving immune cell function

• Neurological disorders:

  • Calcium dysregulation is implicated in numerous neurological conditions

  • Understanding CRACR2B's role in calcium homeostasis could reveal new therapeutic targets

  • Cell type-specific interventions might reduce off-target effects

• Drug development approaches:

  • Small molecule modulators of CRACR2B-Orai1-STIM1 interactions

  • Peptide-based inhibitors targeting specific protein-protein interfaces

  • Gene therapy approaches for conditions with CRACR2B dysfunction

• Biomarker potential:

  • Analysis of CRACR2B expression or post-translational modifications as diagnostic indicators

  • Monitoring CRACR2B/CRACR2A ratios as potential disease markers

Future research should explore these translational directions while continuing to elucidate the fundamental biology of CRACR2B in calcium signaling pathways.